Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jeffrey Lawson

Rheumatology Greenville, SC Medical Doctor

NPI 1790869147 CMS profile 81666

3 Saint Francis Dr, Suite 400, Greenville, SC 29601

Open in the dashboard

General payments

$14,972

878 records reported · program years 2019–2025

Research payments

$1,049

Paid to them · 2 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$355,107 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Jeffrey Lawson of Greenville, SC is reported in the CMS Open Payments database as having received $14,972 across 878 general payments and $1,049 in research payments paid to them. Separately, studies naming them as principal investigator received $355,107 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 79th percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $74 3
2024 General $266 6
2023 General $238 6
2022 General $3,902 220
2022 Research $463 1
2021 General $3,630 196
2020 General $2,731 174
2019 General $4,131 273
2019 Research $586 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jeffrey Lawson
  • Rheumatology median
  • Middle half of Rheumatology
  • National median

In program year 2025, general payments to Jeffrey Lawson were reported at $74. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.

Show as a table
Year Jeffrey Lawson Rheumatology median Middle half National median
2019 $4,131 $744 $153–$2,687 $163
2020 $2,731 $462 $98–$2,027 $114
2021 $3,630 $531 $101–$2,153 $132
2022 $3,902 $627 $125–$2,303 $149
2023 $238 $741 $145–$2,524 $160
2024 $266 $830 $166–$2,660 $164
2025 $74 $903 $171–$2,775 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amgen Inc. $2,099 138 payments
  2. Janssen Biotech, Inc. $1,352 99 payments
  3. AbbVie, Inc. $1,283 58 payments
  4. GlaxoSmithKline, LLC. $1,122 47 payments
  5. Pfizer Inc. $1,074 96 payments
  6. UCB, Inc. $1,038 67 payments
  7. E.R. Squibb & Sons, L.L.C. $885 55 payments
  8. Novartis Pharmaceuticals Corporation $640 41 payments
  9. Horizon Therapeutics plc $586 36 payments
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $556 26 payments
  11. Other $4,338 215 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $14,887 872 payments
  2. Education $86 6 payments
Products named General payments · program years 2019–2025
  1. SIMPONI ARIA $1,180 89 payments
  2. Cimzia $1,022 66 payments
  3. BENLYSTA $997 46 payments
  4. ORENCIA $885 55 payments
  5. XELJANZ $768 59 payments
  6. Enbrel $762 44 payments
  7. RINVOQ $708 30 payments
  8. COSENTYX $654 42 payments
  9. STELARA $626 53 payments
  10. OFEV $556 26 payments
  11. Other $9,865 590 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Eli Lilly and Company $1,049 2 payments

Records

880 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record